Back To: Home : Featured Technology : Assay Development

CLICK HERE FOR WHAT'S NEW IN:
 

Sigma-Aldrich to sell Pfizer’s bioactive small-molecule compounds
May 2010
SHARING OPTIONS:

ST. LOUIS—Sigma-Aldrich has entered into an agreement with Pfizer Inc. to sell approximately 100 Pfizer-developed small-molecule compounds to life science researchers for target characterization, assay development, screening and in vivo animal model applications. The Pfizer compounds, which include patented and approved drug molecules such as atorvastatin, sildenafil and celecoxib, will be made available to the research community while still on patent, in some cases for the first time. Sigma-Aldrich will sell the compounds as in-stock, pre-packaged items and, upon request, in bulk. According to the companies, the inclusion of these Pfizer compounds provides authentic material that will help advance researchers' understanding of biological systems. Financial details were not released. 

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.